B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS

Abstract Background: A previous International Lymphoma Epidemiology (InterLymph) Consortium evaluation of joint associations between five immune gene variants and autoimmune conditions reported interactions between B-cell response-mediated autoimmune conditions and the rs1800629 genotype on risk of B-cell non–Hodgkin lymphoma (NHL) subtypes. Here, we extend that evaluation using NHL subtype-specific polygenic risk scores (PRS) constructed from loci identified in genome-wide association studies of three common B-cell NHL subtypes. Methods: In a pooled analysis of NHL cases and controls of Caucasian descent from 14 participating InterLymph studies, we evaluated joint associations between B-cell–mediated autoimmune conditions and tertile (T) of PRS for risk of diffuse large B-cell lymphoma (DLBCL; n = 1,914), follicular lymphoma (n = 1,733), and marginal zone lymphoma (MZL; n = 407), using unconditional logistic regression. Results: We demonstrated a positive association of DLBCL PRS with DLBCL risk [T2 vs. T1: OR = 1.24; 95% confidence interval (CI), 1.08–1.43; T3 vs. T1: OR = 1.81; 95% CI, 1.59–2.07; P-trend (Ptrend) < 0.0001]. DLBCL risk also increased with increasing PRS tertile among those with an autoimmune condition, being highest for those with a B-cell–mediated autoimmune condition and a T3 PRS [OR = 6.46 vs. no autoimmune condition and a T1 PRS, Ptrend < 0.0001, P-interaction (Pinteraction) = 0.49]. Follicular lymphoma and MZL risk demonstrated no evidence of joint associations or significant Pinteraction. Conclusions: Our results suggest that PRS constructed from currently known subtype-specific loci may not necessarily capture biological pathways shared with autoimmune conditions. Impact: Targeted genetic (PRS) screening among population subsets with autoimmune conditions may offer opportunities for identifying those at highest risk for (and early detection from) DLBCL.

[1]  J. Fellay,et al.  Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma , 2019, Haematologica.

[2]  M. Martinetti,et al.  The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic Review with Meta-analysis , 2019, Disease markers.

[3]  J. Cerhan,et al.  Genetic overlap between autoimmune diseases and non‐Hodgkin lymphoma subtypes , 2019, Genetic epidemiology.

[4]  E. Ben-Chetrit,et al.  Shared Medical and Environmental Risk Factors in Dry Eye Syndrome, Sjogren's Syndrome, and B-Cell Non-Hodgkin Lymphoma: A Case-Control Study , 2019, Journal of immunology research.

[5]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[6]  A. Younes,et al.  High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma. , 2017, Blood reviews.

[7]  Paolo Vineis,et al.  Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia , 2016, Nature Communications.

[8]  Angela Brooks-Wilson,et al.  Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci. , 2015, American journal of epidemiology.

[9]  Paolo Vineis,et al.  A genome-wide association study of marginal zone lymphoma shows association to the HLA region , 2015, Nature Communications.

[10]  Paolo Vineis,et al.  Genome-wide association study identifies multiple susceptibility loci for diffuse large B-cell lymphoma , 2014, Nature Genetics.

[11]  D. Weisenburger,et al.  Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. , 2014, Journal of the National Cancer Institute. Monographs.

[12]  Paolo Vineis,et al.  Genome-wide Association Study Identifies Multiple Risk Loci for Chronic Lymphocytic Leukemia , 2013, Nature Genetics.

[13]  Adele Seniori Costantini,et al.  InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. , 2010, Blood.

[14]  S. Baranzini,et al.  Genetic variation in the odorant receptors family 13 and the mhc loci influence mate selection in a multiple sclerosis dataset , 2010, BMC Genomics.

[15]  D. Hémon,et al.  Increased frequency of hematopoietic malignancies in relatives of patients with lymphoid neoplasms: A French case–control study , 2009, International journal of cancer.

[16]  J. Cerhan,et al.  Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. , 2008, Blood.

[17]  B. Ponder,et al.  Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[18]  J. Cerhan,et al.  Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. , 2008, Blood.

[19]  R. Gascoyne,et al.  Organochlorines and risk of non‐Hodgkin lymphoma , 2007, International journal of cancer.

[20]  D. Weisenburger,et al.  Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). , 2007, Blood.

[21]  E. Holly,et al.  Residential History, Family Characteristics and Non–Hodgkin Lymphoma, A Population-Based Case-Control Study in the San Francisco Bay Area , 2006, Cancer Epidemiology Biomarkers & Prevention.

[22]  H. Adami,et al.  Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. , 2006, Journal of the National Cancer Institute.

[23]  J. Cerhan,et al.  Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. , 2005, American journal of epidemiology.

[24]  J. Kaldor,et al.  Sun exposure may protect against non‐Hodgkin lymphoma: A case‐control study , 2004, International journal of cancer.

[25]  J. Cerhan,et al.  Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26]  M. Forrest,et al.  Body mass index, leptin and leptin receptor polymorphisms, and non-hodgkin lymphoma. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[27]  P. Boyle,et al.  Prior Medical Conditions and Medication use and Risk of non-Hodgkin lymphoma in Connecticut United States Women , 2004, Cancer Causes & Control.

[28]  E. Holly,et al.  Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco. , 2003, American journal of epidemiology.

[29]  A. Silman,et al.  Epidemiology and genetics of rheumatoid arthritis , 2002, Arthritis research.

[30]  O. Nanni,et al.  Haematopoietic cancer and medical history: a multicentre case control study , 2000, Journal of epidemiology and community health.

[31]  P. Donnelly,et al.  Inference of population structure using multilocus genotype data. , 2000, Genetics.

[32]  S. Franceschi,et al.  Medical history and risk of Hodgkin's and non‐Hodgkin's lymphomas , 2000, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[33]  J. Cerhan,et al.  Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. , 2014, Journal of the National Cancer Institute. Monographs.

[34]  J. Cerhan,et al.  Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. , 2014, Journal of the National Cancer Institute. Monographs.

[35]  D. Weisenburger,et al.  Medical history, lifestyle, family history, and occupational risk factors for follicular lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. , 2014, Journal of the National Cancer Institute. Monographs.

[36]  J. Cerhan,et al.  Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. , 2011, International journal of molecular epidemiology and genetics.

[37]  T. Rüdiger,et al.  Medical history and risk for lymphoma: results of a population-based case-control study in Germany. , 2005, European journal of cancer.

[38]  Cdm Fletcher,et al.  World Health Organization Classification of Tumours , 2002 .

[39]  Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region , 2022 .